Abey Hugh T, Fairlie David P, Moffatt James D, Balzary Rowan W, Cocks Thomas M
Department of Pharmacology, The University of Melbourne, Parkville, Australia.
J Pharmacol Exp Ther. 2006 May;317(2):598-605. doi: 10.1124/jpet.105.097121. Epub 2006 Jan 24.
Protective roles for protease-activated receptor-2 (PAR(2)) in the airways including activation of epithelial chloride (Cl(-)) secretion are based on the use of presumably PAR(2)-selective peptide agonists. To determine whether PAR(2) peptide-activated Cl(-) secretion from mouse tracheal epithelium is dependent on PAR(2), changes in ion conductance across the epithelium [short-circuit current (I(SC))] to PAR(2) peptides were measured in Ussing chambers under voltage clamp. In addition, epithelium- and endothelium-dependent relaxations to these peptides were measured in two established PAR(2) bioassays, isolated ring segments of mouse trachea and rat thoracic aorta, respectively. Apical application of the PAR(2) peptide SLIGRL caused increases in I(SC), which were inhibited by three structurally different neurokinin receptor-1 (NK(1)R) antagonists and inhibitors of Cl(-) channels but not by capsaicin, the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37), or the nonselective cyclooxygenase inhibitor indomethacin. Only high concentrations of trypsin caused an increase in I(SC) but did not affect the responses to SLIGRL. Relaxations to SLIGRL in the trachea and aorta were unaffected by the NK(1)R antagonist nolpitantium (SR 140333) but were abolished by trypsin desensitization. The rank order of potency for a range of peptides in the trachea I(SC) assay was 2-furoyl-LIGRL > SLCGRL > SLIGRL = SLIGRT > LSIGRL compared with 2-furoyl-LIGRL > SLIGRL > SLIGRT > SLCGRL (LSIGRL inactive) in the aorta relaxation assay. In the mouse trachea, PAR(2) peptides activate both epithelial NK(1)R coupled to Cl(-) secretion and PAR(2) coupled to prostaglandin E(2)-mediated smooth muscle relaxation. Such a potential lack of specificity of these commonly used peptides needs to be considered when roles for PAR(2) in airway function in health and disease are determined.
蛋白酶激活受体-2(PAR(2))在气道中的保护作用,包括激活上皮氯化物(Cl(-))分泌,是基于使用推测为PAR(2)选择性的肽激动剂。为了确定PAR(2)肽激活的小鼠气管上皮Cl(-)分泌是否依赖于PAR(2),在电压钳制下的尤斯灌流小室中测量了上皮对PAR(2)肽的离子电导变化[短路电流(I(SC))]。此外,分别在两种已建立的PAR(2)生物测定法中测量了这些肽对上皮和内皮的舒张作用,即小鼠气管和大鼠胸主动脉的离体环段。PAR(2)肽SLIGRL经顶端应用可引起I(SC)增加,这被三种结构不同的神经激肽受体-1(NK(1)R)拮抗剂和Cl(-)通道抑制剂所抑制,但不受辣椒素、降钙素基因相关肽(CGRP)受体拮抗剂CGRP(8 - 37)或非选择性环氧化酶抑制剂吲哚美辛的影响。只有高浓度的胰蛋白酶可引起I(SC)增加,但不影响对SLIGRL的反应。气管和主动脉对SLIGRL的舒张作用不受NK(1)R拮抗剂诺匹坦(SR 140333)的影响,但可被胰蛋白酶脱敏所消除。在气管I(SC)测定中,一系列肽的效价顺序为2-糠酰-LIGRL > SLCGRL > SLIGRL = SLIGRT > LSIGRL,而在主动脉舒张测定中为2-糠酰-LIGRL > SLIGRL > SLIGRT > SLCGRL(LSIGRL无活性)。在小鼠气管中,PAR(2)肽激活与Cl(-)分泌偶联的上皮NK(1)R以及与前列腺素E(2)介导的平滑肌舒张偶联的PAR(2)。在确定PAR(2)在健康和疾病状态下气道功能中的作用时,需要考虑这些常用肽可能缺乏特异性的情况。